

List of publications: Prof. Dr. med. Mathias Zink

Disposition

- Original contributions (first author)
- Original contributions (senior author)
- Original contributions (coauthor)
- Review articles
- Case reports and case series
- Books
- Contributions to books

Original contributions (first author)

1. Autosomal-dominant Parkinson's disease linked to 2p13 is not caused by mutations in transforming growth factor alpha (TGF alpha).
Mathias Zink (MD), Lena Grimm (PhD), Zbigniew K. Wszolek (MD), and Thomas Gasser (MD).
Journal of Neural Transmission – General Section 2001; 108 (8-9): 1029 - 1034
2. Differential effects of long-term treatment with clozapine or haloperidol on GABA_A-receptor binding and GAD₆₇-expression.
Mathias Zink, Andrea Schmitt, Brigitte May, Bettina Müller, Traute Demirakca, Dieter F. Braus, and Fritz A. Henn
Schizophrenia Research 2004; 66: 151-157.
3. Differential effects of long-term treatment with clozapine or haloperidol on GABA-transporter expression.
Mathias Zink, Andrea Schmitt, Brigitte May, Bettina Müller, Dieter F. Braus, and Fritz A. Henn
Pharmacopsychiatry. 37(4). July 2004. 171-174
4. Reduced expression of brain-derived neurotrophic factor in mice deficient for pituitary adenylate cyclase activating polypeptide type-I-receptor.
Zink M, Otto C, Zoerner B, Zacher C, Schütz G, Henn FA, Gass P.
Neuroscience Letters 2004; 360: 106-108.
5. Differential expression of glutamate transporters EAAT1 and EAAT2 in mice deficient for PACAP-type I receptor.
Zink M, Schmitt A, Henn FA, Gass P.
Journal of Neural Transmission 2004; 111: 1537-1542.
6. Ethanol induces expression of the glutamate transporters EAAT1 and EAAT2 in organotypic cortical slice cultures.
Zink M, Schmitt A, Vengeliene V, Henn FA, Spanagel R.
Alcoholism: Clinical & Experimental Research 2004; 28(11): 1752-1757.
7. Ethanol induces GAD₆₇ and VGAT in slice cultures of newborn rat cerebral cortex.
Zink M and Spanagel R.
NeuroReport 2005; 16(4):377-380.

8. Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus.
Zink M, Rapp S, Gebicke-Haerter P.J., Henn F A, Thome J
Psychopharmacology 2005; 181: 560 – 565.
9. Reduced expression of complexin I and II in rats bred for learned helplessness.
Mathias Zink (MD), Barbara Vollmayr (MD), Peter J. Gebicke-Haerter (PhD), Fritz A. Henn (MD, PhD), and Johannes Thome (MD, PhD)
Brain Research 2007 May 4;1144: 202-8.
10. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomized controlled clinical trial.
Mathias Zink, Anna Kuwilsky, Bertram Krumm, and Harald Dressing
Journal of Psychopharmacology 2009; 23(3): 305-314.
11. Reduced expression of GABA transporter GAT3 in helpless rats, an animal model of depression.
Zink M, Vollmayr B, Gebicke-Haerter P J, and Henn F A
Neurochemical Research: 2009; 34 (9): 1584-1593.
12. Perinatal exposure to alcohol reduces the expression of complexins I and II.
Mathias Zink, Gülsemin Araç, Stefanie Th. Frank, Peter Gass, Peter J. Gebicke-Härter, Rainer Spanagel
Neurotoxicology and Teratology 2009; 31 (6): 400-405.
13. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression.
Zink M, Vollmayr B, Gebicke-Haerter P J, and Henn F A
Neuropharmacology 2010; 58: 465-463.
14. Fluoxetine-treatment induces the expression of EAAT2 in rat brain.
Zink M (MD), Rapp S (MD), Donev R (PhD), Gebicke-Haerter P J (PhD), and Thome J (MD, PhD)
Journal of Neural Transmission 2011; 118 (6): 849-855.
15. Perinatal exposure to alcohol disturbs spatial learning and glutamate transmission-related gene expression in the adult hippocampus.
Mathias Zink, Thomas Ferbert, Stefanie Th. Frank, Patricia Seufert, Peter J. Gebicke-Haerter, and Rainer Spanagel
European Journal of Neuroscience 2011; 34(3): 457-468.
16. Obsessive-compulsive symptoms in at-risk mental states for psychosis: Associations with clinical impairment and cognitive function
Mathias Zink, Frederike Schirmbeck, Franziska Rausch, Sarah Eifler, Hasan Elkin, Xenia Solojenkina, Susanne Englisch, Michael Wagner, Wolfgang Maier, Marion Lautenschlager, Andreas Heinz, Yehonala Gudlowski, Birgit Janssen, Wolfgang Gaebel, Tanja Maria Michel, Frank Schneider, Martin Lambert, Dieter Naber, Georg Juckel, Seza Krueger-Oezguerdal, Thomas Wobrock, Alkomiet Hasan, Michael Riedel, Hendrik Müller, Joachim Klosterkötter, and Andreas Bechdolf
Acta Psychiatrica Scandinavica Volume 130, Issue 3, September 2014, Pages: 214–226 (doi: 10.1111/acps.12258)

Original contributions (senior author)

1. Duloxetine for major depressive episodes in the course of psychotic disorders: An observational clinical trial.
Susanne Englisch, Udo Knopf, Barbara Scharnholz, Anna Kuwilsky, Michael Deuschle, Mathias Zink
Journal of Psychopharmacology 2009; 23 (8): 875-882.
2. Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats.
Nina Segnitz, Andrea Schmitt (MD), Peter J. Gebicke-Härter (PhD) and Mathias Zink (MD)
Neurochemistry International 2009; 55 (7): 619-628.
3. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
Anna Kuwilsky (MD), Bertram Krumm (PhD), Susanne Englisch (MD), Harald Dressing (MD), and Mathias Zink (MD)
Pharmacopsychiatry 2010; 43 (6): 216-220.
4. Augmentation with Pregabalin in Schizophrenia.
Susanne Englisch (MD), Andrea Eßer (MD), Frank Enning (MD), Sarah Hohmann (MD), Heike Schanz (MD), and Mathias Zink (MD)
Journal of Clinical Psychopharmacology 2010; 30(4): 437-440.
5. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M
Psychological Medicine 2011; 41(11): 2361-2374.
6. Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.
Nina Segnitz (MD), Thomas Ferbert, Andrea Schmitt (MD), Peter Gass (MD), Peter J. Gebicke-Haerter (PhD), and Mathias Zink (MD)
Psychopharmacology 2011; 217: 127-142.
7. Individualizing antipsychotic treatment selection in schizophrenia: Characteristics of empirically derived patient subgroups.
C. U. Corell, F. Cañas; I. Larmo, P. Levy, J.M. Montes, A. Fagiolini , G. Papageorgiou, A. Rossi, R. Sturlason, M. Zink
European Psychiatry 2010; 26: 3-16.
8. Polymorphisms in the glutamate transporter gene *SLC1A1* and obsessive compulsive symptoms induced by second generation antipsychotic agents.
Frederike Schirmbeck, Vanessa Nieratschker, Josef Frank, Susanne Englisch, Franziska Rausch, Andreas Meyer-Lindenberg, Marcella Rietschel and Mathias Zink
Psychiatric Genetics 2012; 22(5): 245-252.
9. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients.

Christine Esslinger, Susanne Englisch, Dragos Inta, Franziska Rausch, Frederike Schirmbeck, Daniela Mier, Peter Kirsch, Andreas Meyer-Lindenberg, Mathias Zink

Schizophrenia Research 2012; 140 (1-3): 114-121.

10. Aripiprazole differentially regulates the expression of Gad67 and γ -amino-butyric acid transporters in rat brain.
Nina Peselmann, Andrea Schmitt, Peter J. Gebicke-Haerter and Mathias Zink
European Archives of Psychiatry and Clinical Neuroscience 2013; 263 (4): 285 - 297
11. Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: A longitudinal study.
Frederike Schirmbeck, Franziska Rausch, Susanne Englisch, Sarah Eifler, Christine Esslinger, Andreas Meyer-Lindenberg, and Mathias Zink
Journal of Psychopharmacology 2013; 27(4): 349 - 357
12. Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: A 12 months longitudinal study.
Frederike Schirmbeck, Franziska Rausch, Susanne Englisch, Sarah Eifler, Christine Esslinger, Andreas Meyer-Lindenberg, and Mathias Zink,
Schizophrenia Bulletin 2013; 39(6):1261 - 1271.
13. The Early Recognition Inventory ERInraos detects at risk mental states of psychosis with high sensitivity
Franziska Rausch, Sarah Eifler, Andrea Esser, Christine Esslinger, Frederike Schirmbeck, Andreas Meyer-Lindenberg, and Mathias Zink
Comprehensive Psychiatry 2013; 54(7):1068-76
14. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study
Wolfgang Weber-Fahr, Susanne Englisch, Andrea Esser, Nuran Tunc-Skarka, Andreas Meyer-Lindenberg, Gabriele Ende, Mathias Zink
Psychiatry Research Neuroimaging 2013; 214(3):365-73
15. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS)
Andreas Schreiner, Anders Svensson, Robert Wapenaar, Pierre Cherubin, Patricia Princet, Larisa Serazetdinova, Mathias Zink
World Journal of Biological Psychiatry 2014. 15(7):534-45. doi:
10.3109/15622975.2014.902990
16. Reduced activation in ventral striatum and ventral tegmental area during probabilistic decision-making in schizophrenia
Franziska Rausch, Daniela Mier, Sarah Eifler, Christine Esslinger, Claudia Schilling, Frederike Schirmbeck, Susanne Englisch, Andreas Meyer-Lindenberg, Peter Kirsch, and Mathias Zink
Schizophrenia Research 2014; Vol. 156, Issues 2-3, p143–149
17. Neurocognitive capabilities modulate the integration of evidence in schizophrenia

Sarah Eifler, Franziska Rausch, Frederike Schirmbeck, Ruth Veckenstedt, Susanne Englisch, Andreas Meyer-Lindenberg, Peter Kirsch, Mathias Zink
Psychiatry Research (doi: 10.1016/j.psychres.2014.04.056. Epub 2014 May 14.)

18. Increased orbitofrontal cortex activation during treatment with 'pro-obsessive' antipsychotic drugs
Frederike Schirmbeck, Daniela Mier, Christine Esslinger, Franziska Rausch, Susanne Englisch, Sarah Eifler, Andreas Meyer-Lindenberg, Peter Kirsch, and Mathias Zink
Journal of Psychiatry and Neuroscience (doi: 10.1503/jpn.140021)
19. Metamemory in schizophrenia: Retrospective confidence ratings interact with neurocognitive deficits.
Eifler S, Rausch F, Schirmbeck F, Veckenstedt R, Mier D, Esslinger C, Englisch S, Meyer-Lindenberg A, Kirsch P, Zink M.
Psychiatry Res. 2014 Dec 2. pii: S0165-1781(14)00932-9. doi: 10.1016/j.psychres.2014.11.040.
20. Reduced activation in ventral striatum during probabilistic decision-making in patients in an at risk mental state
Franziska Rausch, Daniela Mier, Sarah Eifler, Sabrina Fenske, Frederike Schirmbeck, Susanne Englisch, Claudia Schilling, Andreas Meyer-Lindenberg, Peter Kirsch, and Mathias Zink
Journal of Psychiatry and Neuroscience 2015 Jan 27;40(1):140191. doi: 10.1503/jpn.140191
21. Overconfidence in incorrect perceptual judgments in patients with schizophrenia
Steffen Moritz, Nora Ramdani, Helena Klass, Christina Andreou, David Jungclaussen, Sarah Eifler, Susanne Englisch, Frederike Schirmbeck, Mathias Zink
Schizophrenia Research Cognition 2014; 1: 165 – 170
22. Investigation of metamemory functioning in the at risk mental state for psychosis
Sarah Eisenacher, Franziska Rausch, Fabian Ainsler, Daniela Mier, Ruth Veckenstedt, Frederike Schirmbeck, Antje Lewien, Susanne Englisch, Christina Andreou, Steffen Moritz, Andreas Meyer-Lindenberg, Peter Kirsch, Mathias Zink
Psychological Medicine 2015 Nov;45(15):3329-40. doi: 10.1017/S0033291715001373
23. Evaluation of the "Jumping to conclusion" bias in different subgroups of the At-Risk Mental State: from cognitive basic symptoms to UHR- criteria
Franziska Rausch, Sarah Eisenacher, Hasan Elkin, Susanne Englisch, Sarah Kayser, Nadine Striepens, Marion Lautenschlager, Andreas Heinz, Yehonala Gudlowski, Birgit Janssen, Wolfgang Gaebel, Tanja Maria Michel, Frank Schneider, Martin Lambert, Dieter Naber, Georg Juckel, Seza Krueger-Oezguerdal, Thomas Wobrock, Alkomiet Hasan, Michael Riedel, Steffen Moritz, Hendrik Müller, Joachim Klosterkötter, Andreas Bechdorf, Mathias Zink, and Michael Wagner (Both senior authors contributed equally).
Psychological Medicine 2016: 46 (10) - 2071-2081

24. Bias against disconfirmatory evidence (BADE) in the 'at-risk mental state' and during psychosis
Sarah Eisenacher, Franziska Rausch, Daniela Mier, Sabrina Fenske, Ruth Veckenstedt, Susanne Englisch, Anna Becker, Christina Andreou, Steffen Moritz, Andreas Meyer-Lindenberg, Peter Kirsch, Mathias Zink
Psychiatry Research 2016 Apr 30;238:242-50. doi: 10.1016/j.psychres.2016.02.028.
25. Early cognitive basic symptoms are accompanied by neurocognitive impairment in patients with an 'at-risk mental state' for psychosis.
Sarah Eisenacher, Franziska Rausch, Fabian Ainser, Susanne Englisch, Anna Becker, Daniela Mier, Sabrina Fenske, Andreas Meyer-Lindenberg, Peter Kirsch, and Mathias Zink
Early Intervention in Psychiatry 2016 DOI: 10.1111/eip.12350
26. Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: An open-prospective proof-of-concept study.
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, and Mathias Zink
Journal of Clinical Psychopharmacology 2016. 36(6):597-607.
27. Holding on to false beliefs: The bias against disconfirmatory evidence over the course of psychosis
Sarah Eisenacher and Mathias Zink
Journal of Behavior Therapy and Experimental Psychiatry 2016. S0005-7916(16)30089-1. doi: 10.1016/j.jbtep.2016.08.015.
28. Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study.
Englich S^{1,2}, Jung HS³, Lewien A⁴, Becker A¹, Nowak U⁵, Braun H¹, Eisenacher S¹, Thiem J¹, Meyer-Lindenberg A¹, Zink M
Pharmacopsychiatry. 2018 May 7. doi: 10.1055/a-0606-5240.
29. Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression: Results from the AGOPSYCH study.
Susanne Englisch, MD^{1,2}, Hanna Sophie Jung³, Sarah Eisenacher, MSc, PhD¹, Antje Lewien, MD⁴, Anna Becker, MD¹, Ulrike Nowak, MSc⁵, Hanna Braun, MSc¹, Jascha Thiem, MSc¹, Andreas Meyer-Lindenberg, MD, PhD, and Mathias Zink, MD
Journal of Clinical Psychopharmacology. 2018 Aug;38(4):357-361. doi: 10.1097/JCP.0000000000000909
30. Monocausal Attributions Along Cross-Sections of Psychosis Development and Links with Psychopathology and Data Gathering Style
U. Nowak, S. Eisenacher, H. Braun, F. Rausch, S. Muszinski, J. Thiem, A. Becker, S. Englisch, P. Kirsch, A. Meyer-Lindenberg, M. Zink
Cognitive Therapy and Research 2018: 42(5), 699-710
doi: <https://doi.org/10.1007/s10608-018-9907-8>
31. Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine.

Mier D, Schirmbeck F, Stoessel G, Esslinger C, Rausch F, Englisch S, Eisenacher S, de Haan L, Meyer-Lindenberg A, Kirsch P, Zink M. Eur Arch Psychiatry Clin Neurosci. 2018 Dec 11. doi: 10.1007/s00406-018-0965-4.

Original contributions (coauthor)

1. High-Dose clozapine intoxication.
Sartorius A, Hewer W, Zink M, Henn FA.
Journal of Clinical Psychopharmacology 2002; 22(1):91-92.
2. Decreased gene expression of a glial and neuronal glutamate transporter after chronic antipsychotic treatment in rat brain.
Andrea Schmitt, Mathias Zink, Dieter F. Braus, Brigitte May, Bettina Müller, Fritz A. Henn
Neuroscience Letters 2003; 347: 81-84.
3. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits.
Andrea Schmitt, Mathias Zink, Bettina Müller, Brigitte May, Anne Herb, Alexander Jatzko, Dieter F. Braus, Fritz A. Henn
Neurochemical Research 2003; 28(2): 235-241.
4. The effect of antipsychotics on glutamate neurotransmission in animal models. (Die Wirkung von Antipsychotika auf glutamaterge Neurotransmission im Tiermodell).
Andrea Schmitt, Brigitte May, Bettina Müller, Mathias Zink, Dieter F. Braus, Fritz A. Henn
Nervenarzt 2004; 75(1): 16-22.
5. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions.
S. Ridder, S. Chourbaji, R. Hellweg, A. Urani, C. Zacher, W. Schmid, M. Zink, H. Hörtnagl, H. Flor, F.A. Henn, G. Schütz, P. Gass
Journal of Neuroscience 2005;25(26): 6243-50.
6. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors.
Sabine Chourbaji, Alexandre Urani, PhD; Ioana Inta, PhD; Christiane Brandwein; Carles Sanchis-Segura, PhD; Mathias Zink, MD; Markus Schwaninger, MD; Peter Gass, MD
Neurobiology of Disease 2006;23(3):587-94.
7. Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia.
Andrea Schmitt, MD, Markus Fendt, PhD, Mathias Zink, MD, Ulrich Ebert, PhD, Manfred Starke, MD, Mathias Berthold, Anne Herb, PhD, Georg Petroianu, MD, Peter Falkai, MD, Fritz A. Henn, MD, PhD
Journal of Neural Transmission 2007; 114: 239-248.

8. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia.
Andrea Schmitt, MD, Jiri Koschel, MD, Mathias Zink, MD, Manfred Bauer, MD, Clemens Sommer, MD, Josef Frank, MA, Jens Treutlein, PhD, Thomas Schulze, MD, Thomas Schneider-Axmann, Eleni Parlapani, MD, Marcella Rietschel, MD, Peter Falkai, MD, Fritz A Henn, MD, PhD
European Archives of Psychiatry and Clinical Neuroscience 2010; 260 (2): 101-111.
9. MR spectroscopic evaluation of N-acetylaspartate T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia.
Nuran Tunc-Skarka, Wolfgang Weber-Fahr, Mareen Hoerst, Andreas Meyer-Lindenberg, Mathias Zink, Gabi Ende
Neuroimage 2009; 48: 525-531.
10. Increased D-Amino acid oxidase (DAAO) expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study.
Gregor Habl; Mathias Zink, MD; Georg Petroianu, MD, PhD; Manfred Bauer, MD; Thomas Schneider-Axmann; Martina von Wilmsdorff, MD; Peter Falkai, MD; Fritz A Henn, MD, PhD; Andrea Schmitt
Journal of Neural Transmission 2009; 116: 1657-1665.
11. Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia.
J. U. Sommer, A. Schmitt, M. Heck, E. L. Schaeffer, M. Fendt, M. Zink, K. Nieselt, S. Symons, G. Petroianu, A. Lex, M. Herrera-Marschitz, R. Spanagel, P. Falkai, P. J. Gebicke-Haerter
European Archives of Psychiatry and Clinical Neuroscience 2010; 260(Suppl. 2): 81-89.
12. Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe.
G. Papageorgiou, F. Cañas; M. Zink, A. Rossi,
European Psychiatry 2010; 26: 17-28.
13. Decreased reelin expression in the left prefrontal cortex (BA9) in chronic schizophrenia patients.
Gregor Habl, Andrea Schmitt, Mathias Zink, Martina von Wilmsdorff, Peyman Yeganeh-Doost, Alexander Jatzko, Thomas Schneider-Axmann, Manfred Bauer, Peter Falkai
Neuropsychobiology 2012; 66(1): 57-62.
14. Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment.
Martina von Wilmsdorff, MD, Carolin Blaich, MD, Mathias Zink, MD, Jens Treutlein, PhD, Manfred Bauer, MD, Thomas Schulze, MD, Thomas Schneider-Axmann, Oliver Gruber, MD, Marcella Rietschel, MD, Andrea Schmitt, MD, Peter Falkai, MD
The World Journal of Biological Psychiatry 2013; 14 (7) 490 - 499.

15. Reduced striatal activation during reward anticipation due to appetite-provoking cues in chronic schizophrenia: A fMRI study.
Oliver Grimm, Sabine Vollstädt-Klein, Lena Krebs, Mathias Zink, Michael Smolka
Schizophrenia research 2012; 134(2-3): 151-157.
16. Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients.
Andrea Schmitt, Fernando Leonardi-Essmann, Pascal F. Durrenberger, Sven Wichert, Rainer Spanagel, Thomas Arzberger, Hans Kretzschmar, Mathias Zink, Mario Herrera-Marschitz, Richard Reynolds, Moritz Rossner, Peter Falkai and Peter J Gebicke-Haerter
European Archives of Psychiatry and Clinical Neuroscience 2012; 262(7): 565-577.
17. Activation of midbrain and ventral striatal regions implicates salience processing during a modified beads task
Christine Esslinger, Urs Braun, Frederike Schirmbeck, Andreia Santos, Andreas Meyer-Lindenberg, Mathias Zink, Peter Kirsch
PLOS ONE 2013; 8.3 e58536. doi:10.1371/journal.pone.0058536
18. Gene expression in superior temporal cortex of schizophrenia patients
Sellmann, L. Villarín Pildaín, A. Schmitt, F. Leonardi-Essmann, P. F. Durrenberger, R. Spanagel, T. Arzberger, H. Kretzschmar, M. Zink, O. Gruber, M. Herrera-Marschitz, R. Reynolds, P. Falkai, P. J. Gebicke-Haerter, F. Matthäus.
European Archives of Psychiatry and Clinical Neuroscience 2013 (DOI 10.1007/s00406-013-0473-5)
19. Nightmare frequency in schizophrenic patients, healthy relatives of schizophrenic patients, patients at high risk states for psychosis, and healthy controls
Franziska Michels, Claudia Schilling, Franziska Rausch, Sarah Eifler, Mathias Zink, Andreas Meyer-Lindenberg, & Michael Schredl
International Journal of Dream Research Volume 7, No. 1 (2014)
20. Clinical high risk for psychosis: gender differences in symptoms and social functioning
Liz Rietschel, Martin Lambert, Anne Karow, Mathias Zink, Hendrik Müller, Hartmut Stützer, Marion Lautenschlager, Andreas Heinz, Walter de Millas, Birgit Janssen, Wolfgang Gaebel, Tanja Maria Michel, Frank Schneider, Dieter Naber, Georg Juckel, Seza Krüger-Özgürdal, Thomas Wobrock, Michael Riedel, Michael Wagner, Wolfgang Maier, Joachim Klosterkötter and Andreas Bechdolf for the PREVENT study group
Early Intervention in Psychiatry 2015 (in press)
21. Area-specific information processing in prefrontal cortex during a probabilistic inference task: a multivariate fMRI BOLD time series analysis.
Demanele C, Kirsch P, Esslinger C, Zink M, Meyer-Lindenberg A, Durstewitz D.
PLoS One. 2015 Aug 10;10(8):e0135424. doi: 10.1371/journal.pone.0135424.
eCollection 2015.
22. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.

- Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A, Cherubin P, Lahaye M, Hargarter L. Schizophr Res. 2015 Sep 29. pii: S0920-9964(15)00444-2. doi: 10.1016/j.schres.2015.08.015.
23. Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study.
Haro JM, Altamura C, Corral R, Elkis H, Evans J, Malla A, Krebs MO, Zink M, Bernasconi C, Lalonde J, Nordstroem AL.
Schizophr Res. 2015 Sep 29. pii: S0920-9964(15)00470-3. doi: 10.1016/j.schres.2015.09.001.
24. The early recognition inventory ERlraos assesses the entire spectrum of symptoms through the course of an at-risk mental state
Kurt Maurer, Mathias Zink, Franziska Rausch, Heinz Häfner
Early Intervention in Psychiatry 2016. DOI:10.1111/eip.12305
25. Longitudinal association between cognitive performance and obsessive-compulsive symptoms in patients with psychosis and unaffected siblings
Frederike Schirmbeck, Marije Swets, Carin J. Meijer, Mathias Zink, Lieuwe de Haan, Genetic Risk and Outcome of Psychosis (GROUP) investigators (René S. Kahn, Lieuwe de Haan, Jim van Os, Richard Bruggeman, Wiepke Cahn, Agna Bartels, Carin J. Meijer, Inez Myin-Germeys
Acta Psychiatrica Scandinavica 2016 (in press)
26. Investigating the efficacy of an individualized metacognitive therapy program (MCT+) for psychosis: study protocol of a multi-center randomized controlled trial
Brooke Schneider, Ph.D.; Martin Brüne, Dr. med.; Francesca Bohn, MSc; Ruth Veckenstedt, PhD; Katharina Kolbeck, MSc; Eva Krieger, Dipl-Psych; Anna Becker, Dr. med.; Kim Drommelschmidt; Susanne Englisch, Dr. med; Sarah Eisenacher; Sie-In Lee-Grimm, Dr med; Matthias Nagel, Dr. Med.; Mathias Zink, Dr. med.; Steffen Moritz, PhD
BMC Psychiatry 2016, 16:51 (DOI: 10.1186/s12888-016-0756-2)
27. Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study
Stefanie Uhrig, Natalie Hirth, Laura Broccoli, Martina von Wilmsdorff, Manfred Bauer, Clemens Sommer, Mathias Zink, Johann Steiner, Thomas Frodl, Berend Malchow, Peter Falkai, Rainer Spanagel, Anita C. Hansson, Andrea Schmitt
Schizophrenia Research 2016 177(1-3):59-66. doi:10.1016/j.schres.2016.04.019.
28. Fast sleep spindle reduction in schizophrenia and healthy first-degree relatives: association with impaired cognitive function and potential intermediate phenotype
Claudia Schilling, Manuel Schlipf, Simone Spietzack, Franziska Rausch, Sarah Eisenacher, Susanne Englisch, Iris Reinhard, Leila Haller, Oliver Grimm, Michael Deuschle, Heike Tost, Mathias Zink, Andreas Meyer-Lindenberg, Michael Schredl
European Archives of Psychiatry and Clinical Neuroscience 2016 (in press) (DOI: 10.1007/s00406-016-0725-2)
29. Dynamic reconfiguration of brain networks: a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function

Urs Braun, Axel Schäfer, Danielle S. Bassett, Franziska Rausch, Janina Schweiger, Edda Bilek, Susanne Erk, Nina Romanczuk-Seiferth, Oliver Grimm, Lena Geiger, Leila Haddad, Kristina Otto, Sebastian Mohnke, Andreas Heinz, Mathias Zink, Henrik Walter, Emanuel Schwarz, Andreas Meyer-Lindenberg, Heike Tost
PNAS 2016 113(44): 12568-12573.

30. Aberrant activity and connectivity of the posterior superior temporal sulcus during social cognition in schizophrenia
Daniela Mier; Sarah Eisenacher; Franziska Rausch; Susanne Englisch; Martin Fungisai Gerchen; Vera Zamoscik; Andreas Meyer-Lindenberg; Mathias Zink; Peter Kirsch
European Archives of Psychiatry and Clinical Neuroscience 2016.
DOI:10.1007/s00406-016-0737-y
31. Obsessive-compulsive symptoms and overall psychopathology in psychotic disorders: longitudinal assessment of patients and siblings.
Schirmbeck F^{1,2}, Swets M³, Meijer CJ⁴, Zink M⁵, de Haan L^{4,3}; GROUP investigators (Kahn RS, van Os J, Bruggeman R, Cahn W, Bartels-Velthuis AA, Myin-Germeys I.)
Eur Arch Psychiatry Clin Neurosci. 2016. DOI:10.1007/s00406-016-0751-0
32. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
Britta Galling, Alexandra Roldan, Katsuhiko Hagi, Liz Rietschel, Frozan Walyzada, Wei Zheng, Xiao-Lan Cao, Yu-Tao Xiang, Mathias Zink, John M. Kane, Jimmi Nielsen, Stefan Leucht, Christoph U. Correll
World Psychiatry 2017 Feb;16(1):77-89. doi: 10.1002/wps.20387.
33. Negative schemata about the self and others and paranoid ideation in at-risk states and those with persisting positive symptoms
Hendrik Mueller, Walter de Millas, Wolfgang Gaebel, Jutta Herrlich, Alkomiet Hasan, Birgit Janssen, Georg Juckel, Anne Karow, Tilo Kircher, Stefanie Kizskenow-Baeker, Stefan Klingberg, Joachim Klosterkoetter, Seza Krueger-Oezguerdal, Martin Lambert, Marion Lautenschlager, Wolfgang Maier, Tanja Maria Michel, Stefanie Mehl, Bernhard W Mueller, Verena Puetzfeld, Franziska Rausch, Michael Riedel, Gudrun Sartory, Frank Schneider, Michael Wagner, Georg Wiedemann, Andreas Wittorf, Thomas Wobrock, Wolfgang Woelwer, Mathias Zink and Andreas Bechdolf
Early Intervention in Psychiatry 2018 Dec;12(6):1157-1165. doi: 10.1111/eip.12433.
34. Cerebellar volume and cerebello-cerebral structural covariance in schizophrenia - a multi-site mega-analysis of 983 patients and 1349 healthy controls
Torgeir Moberget, Nhat Trung Doan, Dag Alnæs, Tobias Kaufmann, Aldo Palomera, Trine Lagerberg, Jörn Diedrichsen, Emanuel Schwarz, Mathias Zink, Peter Kirsch, Sarah Eisenacher, Erik Jonsson, Helena Fatouros-Bergman, Lena Flyckt, Giulio Pergola, Tiziana Quarto, Alessandro Bertolino, Deanna Barch, Andreas Meyer-Lindenberg, Ingrid Agartz, Ole Andreassen, and Lars Tjelta Westlye

Mol Psychiatry. 2018 Jun;23(6):1512-1520. doi: 10.1038/mp.2017.106. Epub 2017 May 16.

35. Health-related quality of life in outpatients with schizophrenia: factors that determine changes over time
Cristina Domenech, Carlo Altamura, Corrado Bernasconi, Ricardo Corral, Helio Elkis, Jonathan Evans, Ashok Malla, Marie-Odile Krebs, Anna-Lena Nordstroem, Mathias Zink, Josep Maria Haro
Social Psychiatry and Psychiatric Epidemiology 2018 Mar;53(3):239-248. doi: 10.1007/s00127-018-1483-4. Epub 2018 Jan 16.
36. Obsessive–compulsive symptoms in psychotic disorders: longitudinal associations of symptom clusters on between- and within-subject levels
Frederike Schirmbeck, Max Konijn, Vera Hoetjes, Mathias Zink, Lieuwe de Haan, for Genetic Risk and Outcome of Psychosis (GROUP)
European Archives of Psychiatry and Clinical Neuroscience 2018
<https://doi.org/10.1007/s00406-018-0884-4>
37. Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study.
Haro JM¹, Altamura C², Corral R³, Elkis H⁴, Evans J⁵, Krebs MO⁶, Zink M⁷, Malla A⁸, Méndez JI⁹, Bernasconi C¹⁰, Lalonde J¹⁰, Nordstroem AL¹⁰.
Psychiatry Res. 2018 Apr 10;267:56-62. doi: 10.1016/j.psychres.2018.04.005.
38. Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder.
Emanuel Schwarz, Nhat Trung Doan, Giulio Pergola, Lars Tjelta Westlye, Tobias Kaufmann, Thomas Wolfers, Ralph Brecheisen, Tiziana Quarto, Alex Ing, Pasquale Di Carlo, Tiril Gurholt, Robbert Harms, Quentin Noirhomme, Torgeir Moberget, Ingrid Agartz, Ole Andreassen, Marcella Bellani, Alessandro Bertolino, Giuseppe Blasi, Paolo Brambilla, Jan Buitelaar, Helena Fatouros-Bergman, Simon Cervenka, Lena Flyckt, Sophia Frangou, Barbara Franke, Jeremy Hall, Dirk Heslenfeld, Peter Kirsch, Andrew Mcintosh, Andreas Papassotiropoulos, Dominique de Quervain, Marcella Rietschel, Gunter Schumann, Heike Tost, Stephanie Witt, Mathias Zink, Andreas Meyer-Lindenberg, and Markus M. Noethen
Transl Psychiatry. 2019 Jan 17;9(1):12. doi: 10.1038/s41398-018-0225-4.
39. Obsessive-compulsive symptoms and overall psychopathology in psychotic disorders: longitudinal assessment of patients and siblings.
Schirmbeck F, Swets M, Meijer CJ, Zink M, de Haan L; GROUP investigators.
Eur Arch Psychiatry Clin Neurosci. 2018 Apr;268(3):279-289. doi: 10.1007/s00406-016-0751-0. Epub 2016 Dec 17.
40. Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk.
Alnæs D, Kaufmann T, van der Meer D, Córdova-Palomera A, Rokicki J, Moberget T, Bettella F, Agartz I, Barch DM, Bertolino A, Brandt CL, Cervenka S, Djurovic S, Doan NT, Eisenacher S, Fatouros-Bergman H, Flyckt L, Di Giorgio A,

Haatveit B, Jönsson EG, Kirsch P, Lund MJ, Meyer-Lindenberg A, Pergola G, Schwarz E, Smeland OB, Quarto T, Zink M, Andreassen OA, Westlye LT; Karolinska Schizophrenia Project Consortium.
JAMA Psychiatry. 2019 Apr 10. doi: 10.1001/jamapsychiatry.2019.0257.

41. Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study.
Freitas R, Dos Santos B, Altamura C, Bernasconi C, Corral R, Evans J, Malla A, Krebs MO, Nordstroem AL, Zink M, Haro JM, Elkis H.
Psychiatry Res. 2019 Jun;276:210-217. doi: 10.1016/j.psychres.2019.05.002.
Epub 2019 May 8.
42. A randomized double-blind controlled trial to assess the benefits of Amisulpride and Olanzapine combination treatment vs. each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Pablo-Emilio Verde, Henrike Kolbe, Christoph U. Correll, Stefan Leucht, Stephan Heres, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm Poepl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Thomas Wobrock, Joachim Cordes.
European Archives of Psychiatry and Clinical Neuroscience 2019 (in press)
<https://doi.org/10.1007/s00406-019-01063-4>
43. Common brain disorders are associated with heritable patterns of apparent aging of the brain
Tobias Kaufmann 1*, Dennis van der Meer^{1,2}, Nhat Trung Doan¹, Emanuel Schwarz³, Martina J. Lund¹, Ingrid Agartz^{1,4,5}, Dag Alnas 1, Deanna M. Barch^{6,7,8}, Ramona Baur-Streubel⁹, Alessandro Bertolino^{10,11}, Francesco Bettella¹, Mona K. Beyer^{12,13}, Erlend Boen⁴, Stefan Borgwardt ^{14,15,16}, Christine L. Brandt¹, Jan Buitelaar ^{17,18}, Elisabeth G. Celius ^{12,19}, Simon Cervenka⁵, Annette Conzelmann²⁰, Aldo Córdova-Palomera¹, Anders M. Dale^{21,22,23,24}, Dominique J. F. de Quervain^{25,26}, Pasquale Di Carlo ¹¹, Srdjan Djurovic ^{27,28}, Erlend S. Dorum^{1,29,30}, Sarah Eisenacher³, Torbjorn Elvsashagen^{1,12,19}, Thomas Espeseth ²⁹, Helena Fatouros-Bergman⁵, Lena Flyckt⁵, Barbara Franke ³¹, Oleksandr Frei¹, Beathe Haatveit^{1,29}, Asta K. Haberg^{32,33}, Hanne F. Harbo^{12,19}, Catharina A. Hartman³⁴, Dirk Heslenfeld^{35,36}, Pieter J. Hoekstra³⁷, Einar A. Hogestol^{12,19}, Terry L. Jernigan^{38,39,40}, Rune Jonassen⁴¹, Erik G. Jönsson^{1,5}, Karolinska Schizophrenia Project (KaSP)⁴², Peter Kirsch ^{43,44}, Iwona Kłozewska⁴⁵, Knut K. Kolskar^{1,29,30}, Nils Inge Landro^{29,4}, Stephanie Le Hellard²⁸, Klaus-Peter Lesch ^{46,47,48}, Simon Lovestone⁴⁹, Arvid Lundervold ^{50,51}, Astri J. Lundervold ^{52,53}, Luigi A. Maglanoc^{1,29}, Ulrik F. Malt ^{12,54}, Patrizia Mecocci⁵⁵, Ingrid Melle¹, Andreas Meyer-Lindenberg ³, Torgeir Moberget¹, Linn B. Norbom^{1,29}, Jan Egil Nordvik⁵⁶, Lars Nyberg⁵⁷, Jaap Oosterlaan^{35,58}, Marco Papalino¹¹, Andreas Papassotiropoulos^{59,26,60}, Paul Pauli ⁹, Giulio Pergola ¹¹, Karin Persson^{61,62}, Genevieve Richard^{1,29,30}, Jaroslav Rokicki^{1,29}, Anne-Marthe Sanders^{1,29,30}, Geir Selbak^{62,63,64}, Alexey A. Shadrin¹, Olav B. Smeland ¹,

Hilkka Soininen^{65,66}, Piotr Sowa¹³, Vidar M. Steen^{28,67}, Magda Tsolaki⁶⁸, Kristine M. Ulrichsen^{1,29,30}, Bruno Vellas⁶⁹, Lei Wang⁷⁰, Eric Westman^{71,16}, Georg C. Ziegler⁴⁶, Mathias Zink^{3,72}, Ole A. Andreassen¹ and Lars T. Westlye^{1,29*}

Nature Neuroscience 2019 (in press) <https://doi.org/10.1038/s41593-019-0471-7>.

Review articles:

1. Combination of clozapine and amisulpride in treatment-resistant schizophrenia – case reports and review of the literature.
Mathias Zink, Udo Knopf, Fritz A. Henn, Johannes Thome
Pharmacopsychiatry 2004; 37(1): 26-31.
2. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.
Mathias Zink, Fritz A. Henn and Johannes Thome
European Psychiatry 2004; 19(1): 56-58.
3. Augmentation of clozapine with atypical antipsychotic substances.
Zink M, Dressing H
Current Psychiatry Reviews 2005; 1(2): 165-172.
4. Clozapin-Augmentation mit atypischen Antipsychotika.
Zink M and Dressing H
Nervenarzt 2005; (76) 1092-1102.
5. Augmentation of olanzapine in treatment resistant schizophrenia
Mathias Zink
Journal of Psychiatry and Neuroscience 2005; 30(6): 409-415.
6. Optimierung der antipsychotischen Therapie mit Olanzapin durch Augmentationsstrategien: Eine kritische Literaturübersicht.
Mathias Zink
Psychiatrische Praxis 2006; 33: 261-268.
7. Kombinierte antipsychotische Therapie mit Clozapin und Aripiprazol.
Mathias Zink (MD)
Nervenheilkunde 2007; 26: 1029-1035.
8. Die molekulare Neurobiologie schizophrener Psychosen.
Mathias Zink, Andreas Meyer-Lindenberg
Nervenheilkunde 2007; 26: 882-890.
9. Neurobiology confirms Psychopathology: On the antagonism of psychosis and obsessive-compulsive syndromes.
Mathias Zink (MD), Susanne Englisch, Harald Dressing (MD)
Psychopathology 2008. 41: 279-285.
10. Combined antipsychotic treatment involving clozapine and aripiprazole.
Susanne Englisch and Mathias Zink (MD)

Progress in Neuropsychopharmacology and Biological Psychiatry 2008; 32(6): 1386-92.

11. A Roadmap to disentangle the Molecular Etiology of Schizophrenia.
Peter Falkai, Wolfgang Maier, Markus Nöthen, Philip McGuire, Mike Owen, Franck Schürhoff, Eduard Maron, Inez Myin-Germeys, Andreas Meyer-Lindenberg, Mathias Zink, Neeltje van Haren, Stephen Lawrie, Nicholas Stefanis, Wolfgang Wölwer, Elisabetta Vaudano, Sagiv Shifman, Andras Bilkei-Gorzo, Paul Harrison, Marc de Hert, István Bitter, Thomas Dierks, Siegfried Kasper, Antonio Vita, Benedicto Crespo-Facorro, Annabella di Giorgio, Stephan Ruhrmann, Albert Gjedde, Sophia Frangou
European Psychiatry 2008; 23(4): 224-232.
12. Kardiale Sicherheit antipsychotischer Therapie.
Mathias Zink
Internistische Praxis 2009; 49(1): 110-112.
13. Polypharmacy in schizophrenia.
Mathias Zink, Susanne Englisch, Andreas Meyer-Lindenberg
Current Opinion in Psychiatry 2010; 23(2): 103-111.
14. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A, Cañas F, Gallhofer B, Larmo I, Levy P, Montes JM, Papageorgiou G, Zink M and Rossi A
Expert Opinion on Pharmacotherapy 2010; 11(13): 1-22.
15. Polypharmazie bei schizophrenen Psychosen.
Mathias Zink, Susanne Englisch, Andreas Meyer-Lindenberg
Der Nervenarzt 2011; 82: 853-858.
16. Kardiale Sicherheit antipsychotischer Therapie.
Mathias Zink
Tägliche Praxis 2010; 51(4): 806-808.
17. Zwangssyndrome bei Schizophrenie.
Schirmbeck F and Zink M
Ärztliche Praxis Neurologie Psychiatrie 2011; (1): 20-22.
18. Switching Among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone.
Alessandro Rossi, MD; Fernando Cañas, MD; Andrea Fagiolini, MD; Ilkka Larmo, MD; Pedro Levy, MD; José Manuel Montes, MD; Georgios Papageorgiou, MD; Runa Sturlason, MD; Mathias Zink, MD; and Christoph U. Correll, MD
Postgraduate Medicine 2011; 123 (1): 135-159.
19. Mixed results for aripiprazole augmentation in non-responders to clozapine
Commentary on Muscatello et al. (2011).
Mathias Zink
The Brown University Psychopharmacology Update July 2011.
20. Practical Guidance for Prescribing Ziprasidone in Acute Manic or Mixed Episodes of Bipolar I disorder.

Cañas F, Correll CU, Fagiolini A, Larmo I, Levy P, Papageorgiou G, Rossi A, Sturlason R, Zink M, Montes J-M
Expert Opinion in Pharmacotherapy 2011; 12(14): 2245-2263.

21. Wenn Ängste zum Wahn werden.
Andrea Esser, Franziska Rausch, Mathias Zink
Medical Tribune Neurologie Psychiatrie 2011; 2: 17.
22. Combination and Augmentation Strategies in Treatment-resistant Schizophrenia.
Susanne Englisch and Mathias Zink
Drug Discovery Today: Therapeutic Strategies 2011; 8(1-2): 17-23.
23. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: A critical review.
Frederike Schirmbeck and Mathias Zink
Current Neuropharmacology 2012; 10(1): 88-95.
24. Treatment resistant schizophrenia: Evidence-based strategies.
Susanne Englisch and Mathias Zink
Mens Sana Monographs 2012; 10: 20-32.
25. Obsessiv-kompulsive Symptome bei Schizophrenie
Frederike Schirmbeck, Mathias Zink
Psychiatrie und Psychotherapie up2date 2013; 7(3): 161 - 173
26. Cognitive-behavioural therapy for obsessive-compulsive symptoms in schizophrenia
Frederike Schirmbeck and Mathias Zink
The Cognitive Behavioural Therapist 2013
DOI: <http://dx.doi.org/10.1017/S1754470X13000123>
27. State of the art: Schizophrenie
Susanne Englisch, Mathias Zink
Pharma Fokus ZNS 2013; 10: 30-32
28. Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors
Frederike Schirmbeck and Mathias Zink
Frontiers in Neuropharmacology 2013; 4: 99
doi10.3389/fphar.2013.00099
28. Risks and benefits of Bupropion treatment in Schizophrenia: A systematic review of the current literature.
Susanne Englisch, Katrin Morgen, Andreas Meyer-Lindenberg, and Mathias Zink
Clinical Neuropharmacology 2013; 36(6):203-15
29. Schizophrenie verstehen lernen: Psychoedukative Gruppen am ZI entlasten und stärken Angehörige
Sarah Eifler, Frederike Schirmbeck, Franziska Rausch, Mathias Zink
gesundheitspress 46/2013
30. Schizophrenie: Ratgeber Psychosen

Spektrum der Wissenschaft – Gehirn und Geist
Mathias Zink, Franziska Rausch, Sarah Eifler,
2014 (Heft 07.08.2014)

31. State of the art: Schizophrenie
Susanne Englisch, Mathias Zink
Pharma Fokus ZNS 2014; 11: 44 - 46
32. Unterbringung und Betreuung: Formale Grundlagen und aktuelle Praxis
Harald Dressing und Mathias Zink
Psychiatrie und Psychotherapie up2date 2014 (doi: 10.1055/s-0034-1370034)
33. Comorbid obsessive-compulsive symptoms in schizophrenia: Insight into pathomechanisms facilitates treatment
Mathias Zink
Advances in Medicine: Psychiatry (<http://dx.doi.org/10.1155/2014/317980>)
34. Antipsychotic treatment modulates glutamate transport and NMDA receptor expression
Mathias Zink, Susanne Englisch and Andrea Schmitt
European Archives of Psychiatry and Clinical Neuroscience 2014
(doi: 10.1007/s00406-014-0534-4. Epub 2014 Sep 12)
35. Glutamatergic agents for schizophrenia: Current evidence and perspectives
Mathias Zink and Christoph U Correll
Expert Reviews of Clinical Pharmacology 2015 May;8(3):335-52
36. State of the art: Schizophrenie
Susanne Englisch, Mathias Zink
Pharma Fokus ZNS 2015 12 (1): 39 - 40
37. Obsessiv-kompulsive Syndrome bei Psychosen
Frederike Schirmbeck, Mathias Zink
neuro aktuell 2015
38. Schizophrenia therapy: An obstacle course
Comment in Lancet psychiatry
Mathias Zink and Susanne Englisch
Lancet Psychiatry 2016 ([http://dx.doi.org/10.1016/S2215-0366\(16\)00023-7](http://dx.doi.org/10.1016/S2215-0366(16)00023-7))
39. State of the Art: Psychosen aus dem schizophrenen Formenkreis: Übersieht die naturwissenschaftliche Reduktion das Subjekt?
Susanne Englisch, Mathias Zink
Pharmafokus 2016
40. The importance of metamemory functioning to the pathogenesis of psychosis
Sarah Eisenacher, Mathias Zink
Frontiers in Psychology, section Consciousness Research 2017 (in press) doi:
10.3389/fpsyg.2017.00304
41. State of the Art: Psychosen aus dem schizophrenen Formenkreis: Wege aus der Stigmatisierungsfalle

Susanne Englisch, Mathias Zink
Pharma Fokus ZNS 2017

42. State of the Art: Psychosen aus dem schizophrenen Formenkreis: Fortschritte in der Forschung, Rückschritte in der Versorgung?
Susanne Englisch, Mathias Zink
Pharma Fokus ZNS 2018 15 (1): 22 – 25
43. Schizophrenien, schizophreniforme und wahnhafte Störungen: Akute psychotische Störungsbilder
Susanne Englisch, Mathias Zink
PSYCH up2date 2019; 13 (6): 1–18 DOI: 10.1055/a-0826-0964
44. PharmaFokus - Kompendium ZNS 2019
Psychosen aus dem schizophrenen Formenkreis
Susanne Englisch, Mathias Zink
Pharma Fokus ZNS 2018 15 (1): 22 – 25

Case reports and case series:

1. Electroconvulsive therapy in a patient receiving rivastigmine.
Mathias Zink, Alexander Sartorius, Florian Lederbogen, and Fritz A. Henn
Journal of ECT 2002; 18(3): 162-164.
2. Remission of polydipsia as antipsychotic effect of clozapine.
Zink M, Sartorius A, and Lederbogen F
European Psychiatry: The Journal of the Association of European Psychiatrists
2004; 19(5): 320-321.
3. Ziprasidone-Augmentation of Clozapine.
Zink M, Mase E, Dressing H
Psychiatrische Praxis 2004; 31(5): 259-261.
4. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Zink M, Mase E, Dressing H
Human Psychopharmacology 2004; 19(4): 271-273.
5. A case of Pulmonary Thrombembolism and Rhabdomyolysis during Therapy with Mirtazapine and Risperidone.
Zink M, Knopf U, Argiriou S and Kuwilsky A
Journal of Clinical Psychiatry 2006; 67(5): 835.
6. Duloxetine treatment of major depressive episodes in the course of psychotic disorders.
Mathias Zink, Udo Knopf, Evelyn Mase, Anna Kuwilsky, and Michael Deuschle
Pharmacopsychiatry 2006; 39: 109-111.
7. Dyskinesia during treatment with duloxetine.
Michael Deuschle, Evelyn Mase, Mathias Zink
Pharmacopsychiatry 2006; 39: 236-238.
8. Olanzapine-associated bilateral eyelid edema.

Mathias Zink MD, Anna Kuwilsky, Udo Knopf MD
Journal of Clinical Psychopharmacology 2007; 27(2) 214.

9. Management of clozapine-induced obsessive compulsive symptoms in man with schizophrenia.
Mathias Zink, Udo Knopf, Anna Kuwilsky
Australian and New Zealand Journal of Psychiatry 2007; 41 (3): 293-294.
10. Augmentation of clozapine with valproic acid for clozapine-induced obsessive-compulsive symptoms.
Mathias Zink (MD), Susanne Englisch, Udo Knopf (MD), Anna Kuwilsky, and Harald Dressing(MD)
Pharmacopsychiatry 2007; 40, 202-203.
11. Urinary retention during combined treatment of post-psychotic depression with duloxetine and olanzapine.
Susanne Englisch, Michael Fritzing (MD), and Mathias Zink (MD)
Clinical Neuropharmacology 2008; 31(5): 307-309.
12. Risperidone-associated increase in triglyceride levels.
Andrea Weinbrenner, Verena Peus, Dragos Inta, Susanne Englisch, Mathias Zink
American Journal of Psychiatry 2009; 166(1): 113-114.
13. Aripiprazole-monotherapy for Tourette syndrome accompanied by obsessive-compulsive symptoms.
Dragos Inta, Susanne Englisch, Mathias Zink
German Journal of Psychiatry 2008; 11: 123-125.
14. Aripiprazole for the management of Olanzapine-induced weight gain
Englich S, Weinbrenner A, Inta D, and Zink M
Pharmacopsychiatry 2009; 42:166-167.
15. Clozapine-induced obsessive compulsive syndromes improve in combination with aripiprazole.
Susanne Englisch, Christine Esslinger, Dragos Inta, Andrea Weinbrenner, Verena Peus, Alexander Gutschalk, Frederike Schirmbeck and Mathias Zink
Clinical Neuropharmacology 2009; 32(4): 227-229.
16. Bupropion for depression in schizophrenia: A case report.
Susanne Englisch, Andrea Esser, Mathias Zink
Pharmacopsychiatry 2010; 43: 38-39.
17. Clozapine combined with Paliperidone: Observations in schizophrenic patients with insufficient responses to clozapine-monotherapy.
Christine Esslinger, Dragos Inta, Susanne Englisch, Andrea Esser and Mathias Zink
German Journal of Psychiatry 2010; 13 (1): 37-40.
18. fMRI in prodromal schizophrenia: A case report.
Grimm O., Kersting J.-P., Zink M., Gass P.
German Journal of Psychiatry 2010; 13 (1): 57-60.

19. Quetiapine-associated increase of triglycerides.
Zink M., Marquardt L., Sartorius A.
Journal of Clinical Psychiatry 2010; 71(11): 1554-1555.
20. Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine-monotherapy.
Susanne Englisch (MD), Frank Enning (MD), Martin Grosshans (MD), Lars Marquardt (MD, PhD), Robert Waltereit (MD), and Mathias Zink (MD)
Clinical Neuropharmacology 2010; 33(5): 227-229.
21. Bupropion for depression in schizophrenia.
Susanne Englisch, Dragos Inta, Andrea Eßer, and Mathias Zink
Clinical Neuropharmacology 2010; 33(5): 257-259.
22. Pregabalin-associated increase of clozapine serum levels.
Susanne Englisch, Barbara Alm, Andreas Meyer-Lindenberg and Mathias Zink
Journal of Clinical Psychopharmacology 2012; 32(1): 127
23. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.
Sandra Schönfelder, Frederike Schirmbeck, Robert Waltereit, Susanne Englisch, Mathias Zink
Clinical Neuropharmacology 2011; 34(6): 256-257
24. Psychopathologie bei hypodensen Basalganglienläsionen.
Früh-Manifestation kognitiv-mnestischer Defizite bei einem 18-jährigen Patienten mit familiärer Neurodegeneration mit Eisenakkumulation im Gehirn.
Andrea Eßer, Franziska Rausch, Sarah Eifler, Mathias Zink
Der Nervenarzt 2013; 84: 851 - 853
25. Visual and auditory hallucinations associated with citalopram treatment.
Robert Waltereit, Sarah Eifler, Frederike Schirmbeck and Mathias Zink
Journal of Clinical Psychopharmacology 2013; 33(4):583-4
26. Schizophreniform psychosis during treatment with alitretinoin
Bumb, J.M.; Solojenkina, X.; Zink, M.
Journal of Clinical Psychopharmacology 2015 Oct;35(5):612

Books:

1. Plastizität der Hirnentwicklung als Perspektive psychiatrischer Grundlagenforschung
Mathias Zink
Shaker Verlag: Online-Publication 2007
DOI-Number: 10.2370/210_194
2. Obsessive-compulsive symptoms in Schizophrenia
Lieuwe de Hann, Frederike Schirmbeck, Mathias Zink (editors)
Springer 2015
ISBN-10: 3319129511
ISBN-13: 978-3319129518

Contributions to books:

1. Synaptic Pathology in Depression
Barbara Vollmayr, Fritz A. Henn and Mathias Zink
In: Molecular Mechanisms in Synaptogenesis
Springer 2006, Editors: Alexander Dityatev and Alaa El-Husseini (Chapter 28), 419-430.
2. The hypoxic rat model for obstetric complications in schizophrenia
Andrea Schmitt, Peter Gebicke-Haerter, Ulrich Sommer, Markus Heck, Anja Lex, Mario Herrera-Marschitz, Mathias Zink, Markus Fendt, Peter Falkai
In: Animal Models of Schizophrenia.
Humana press (Springer); Editor: Patricio O'Donnell.
Series: Neuromethods | Volume: 59 | Pub. Date: Jul-01-2011 | Page Range: 93-111 | DOI: 10.1007/978-1-61779-157-4_4
3. Alkohol und Tabak in der Schwangerschaft
Regina Rasenack und Mathias Zink
In: Singer/Batra/Mann: Alkohol, Tabak und Folgeerkrankungen
Thieme Verlag 2011.
4. Neurobiology of Alcohol Addiction
Rainer Spanagel, Mathias Zink, Wolfgang Sommer
In: Donald Pfaff (Editor in Chief): Neuroscience in the 21. Century
Springer Verlag 2013, pp 2745-2773
5. Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy?
Frederike Schirmbeck and Mathias Zink
In: Polypharmacy in Psychiatric Practice
Springer Verlag; Editor: Michael Ritsner; 2013
6. Kapitel 3: Depressive Episoden bei schizophrenen Psychosen
Dr. Susanne Englisch & Prof. Dr. Mathias Zink
In Psychopharmakotherapie bei speziellen Patientengruppen“ Hrsg: PD Dr. Dr. Niels Bergemann, Prof. Dr. Thomas Messer
2019 (In press)

7. Kapitel 5: Psychopharmakotherapie obsessiv-kompulsiver Symptome bei Schizophrenie
Dr. Frederike Schirmbeck & Prof. Dr. Mathias Zink
In Psychopharmakotherapie bei speziellen Patientengruppen“ Hrsg: PD Dr. Dr. Niels Bergemann, Prof. Dr. Thomas Messer
2019 (In press)